News >

Expert Explains Work Needed for Immunotherapy/RT Approaches in NSCLC

Caroline Seymour
Published: Wednesday, Aug 15, 2018

James Larner, MD

James Larner, MD

In non–small cell lung cancer (NSCLC), determining whether radiation can truly potentiate response to immunotherapy requires a better understanding of underlying permutations and pathways, explained James Larner, MD.

on Advanced Non–Small Cell Lung Cancer, Larner discussed the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with NSCLC.

OncLive: What is the role of radiation therapy in combination with immune-oncology agents?

Larner: Immunotherapy has had a tremendous impact on lung cancer and other solid tumors. The real question in my mind is, “Why do patients become resistant to immunotherapy?” If we can figure out the mechanisms of resistance, we have the potential to manipulate the system, invert resistance, and increase response rates. Historically, radiation has been thought of as a DNA-damaging agent.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication